FDA affirms its position against using picamilon in dietary supplements by following up testimony an agency official made in state enforcement litigation with warnings to five firms marketing supplements containing the ingredient.
The Nov. 30 letters could mark the start of a sweep to rid the US market of products containing the ingredient that the agency initially identified as violative in a Sept. 28 declaration submitted for a civil complaint the Oregon attorney general filed against [GNC Holdings Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?